Basel, 18 May 2017
Invitation: Roche Analyst Event at ISTH 2017
Monday, 10 July 2017, 6:30pm CEST
We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017.
During the briefing, Roche will discuss new data for emicizumab (ACE910) in hemophilia A:
HAVEN1 - phase 3 study of emicizumab (ACE910) prophylaxis in persons with hemophilia A with inhibitors
HAVEN2 - phase 3 study of emicizumab (ACE910) in pediatric persons with hemophilia A with inhibitors
Monday, 10 July 2017
6:00pm Registration desk opens
6:30pm Start of meeting
7:45pm End of meeting followed by a buffet reception
Hotel Berlin, Berlin
To register for the event, please follow the link (Password: Analyst2017).
Dial in to the conference 10-15 minutes prior to the scheduled start, using the following dial-in numbers (listen-only mode, no live-access to speakers):
+41 (0) 58 310 5000 (Europe and ROW) or
+44 (0) 203 059 5862 (UK) or
+1 (1) 631 570 5613 (USA)
Alternatively a live audio webcast can be accessed via http://ir.roche.com. The presentation slides will be available from the IR website at http://ir.roche.com following to the closure of the ISTH meeting.
A replay of the webcast will be available on demand on the Roche website.
Head of Investor Relations
Investor Relations Officer